Chronic myeloid leukemia: the basis of treatment for tomorrow

Simple item page
dc.contributor.authorCarella, A.M.
dc.contributor.authorGoldman, J.M.
dc.contributor.authorMartinelli, G.
dc.contributor.authorMelo, J.V.
dc.contributor.authorPerrotti, D.
dc.date.issued2011
dc.description.abstractRecent years have seen dramatic advances in deciphering the molecular pathogenesis of chronic myeloid leukemia (CML). This has resulted in the rapid development of many BCR-ABL1-specific tyrosine kinase inhibitors (TKI) which have improved 10-year survival to more than 80%. In this paper we focus on some future directions for CML biology and therapy.
dc.description.statementofresponsibilityAngelo M. Carella, John M. Goldman, Giovanni Martinelli, Junia V. Melo, Danilo Perrotti
dc.identifier.citationHaematologica: the hematology journal, 2011; 96(12):1737-1739
dc.identifier.doi10.3324/haematol.2011.052571
dc.identifier.issn0390-6078
dc.identifier.issn1592-8721
dc.identifier.urihttp://hdl.handle.net/2440/91137
dc.language.isoen
dc.publisherFerrata Storti Foundation
dc.rightsCopyright © Ferrata Storti Foundation
dc.source.urihttps://doi.org/10.3324/haematol.2011.052571
dc.subjectNeoplastic Stem Cells
dc.titleChronic myeloid leukemia: the basis of treatment for tomorrow
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications